FzM1.8 is a small molecule, allosteric agonist of the Frizzled receptor Fzd4 with pEC50 of 6.4, potentiates β-catenin pathway in the absence of any WNT ligand; biases FZD4 signaling toward a FZD4/PI3K axis that culminates into transactivation of β-catenin/TCF activity by the histone acetyltransferase CBP/p300; preserves stemness and promotes proliferation of undifferentiated cells.
SRI 37892 (SRI37892) is a novel potent, small molecule Frizzled 7 (Fzd 7) inhibitor with IC50 of 0.66 uM in Wnt/β-catenin assay; also displays potent activity against Wnt/β-catenin signaling in LRP6-expressing HEK293 cells with IC50 of 0.78 uM, demonstrates potent activity against breast cancer HS578T and BT549 cell proliferation with IC50 of 2.2 and 1.9 uM, respectively; targets Fzd7 transmembrane domain (TMD) and bolcks Wnt/Fzd7 signaling.
Join with Us
Product Use Citations
Pharmacological Glossary Abbreviations
How to Order
Terms & Conditions
Credit Card Payment
Shipping Rates & Policies